title: Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada.
abstract: To estimate cost-effectiveness of routine and catch-up vaccination of Canadian children with seven-valent pneumococcal conjugate vaccine, a simulation model was constructed. In base scenario (vaccination coverage: 80%, and vaccine price: 58 dollars per dose), pneumococcal disease incidence reduction would be superior to 60% for invasive infections, and to 30% for non-invasive infections, but the number of deaths prevented would be small. Annual costs of routine immunization would be 71 million dollars (98% borne by the health system). Societal benefit to cost ratio would be 0.57. Net societal costs per averted pneumococcal disease would be 389 dollars and 125,000 per life-year gained (LYG). Vaccine purchase cost is the most important variable in sensitivity analyses, and program costs would be superior to societal benefits in all likely scenarios. Vaccination would result in net savings for society, if vaccine cost is less than 30 dollars per dose. Economic indicators of catch-up programs are less favorable than for routine infant immunization.
authors.affiliation: Department of Social and Preventive Medicine, Laval University, Quebec City, Que., Canada G1K 7P4. philippe.dewals@msp.ulaval.ca
authors.forename: Philippe
authors.initials: P
authors.lastname: De Wals
authors.forename: Geneviève
authors.initials: G
authors.lastname: Petit
authors.forename: Lonny James
authors.initials: LJ
authors.lastname: Erickson
authors.forename: Maryse
authors.initials: M
authors.lastname: Guay
authors.forename: Theresa
authors.initials: T
authors.lastname: Tam
authors.forename: Barbara
authors.initials: B
authors.lastname: Law
authors.forename: Alicia
authors.initials: A
authors.lastname: Framarin
mesh_terms: D000465:Algorithms; D002170:Canada / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003198:Computer Simulation; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016208:Databases, Factual; D016527:Drug Costs; D005260:Female; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007117:Immunization, Secondary / Q000191:economics; D007223:Infant; D008297:Male; D018803:Models, Economic; D011008:Pneumococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics* / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000191:economics / Q000276:immunology
chemical_list: D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate